Anavex net loss narrows to $5.3 million in Q2 FY26; R&D expenses drop to $4.2 million - AVXL News | RalliesAnavex net loss narrows to $5.3 million in Q2 FY26; R&D expenses drop to $4.2 million
A
AVXL• Quarterly results and expenses
- Anavex posted a GAAP net loss of $5.3 million, or $0.06 per share, for fiscal Q2 ended March 31, 2026.
- R&D expense fell to $4.19 million from $9.89 million a year earlier, due to completing the ANAVEX 3-71 schizophrenia trial.
- G&A costs edged down to $2.29 million from $2.62 million in the year-ago quarter.
Cash position and clinical updates
- Cash and cash equivalents rose to $127.4 million as of March 31, 2026; the company expects funding into mid-to-late fiscal 2028.
- Anavex opened an FDA IND for early Alzheimer’s at end-March; DDI dosing is underway, and ADME study initiation is targeted for calendar Q3 2026.
CROX
•
